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Abstract
Background: The accurate diagnosis of TB in HIV-infected patients, particularly with advanced immunosuppression, is
difficult. Recent studies indicate that a lipoarabinomannan (LAM) assay (Clearview-TBH-ELISA) may have some utility for the
diagnosis of TB in HIV-infected patients; however, the precise subgroup that may benefit from this technology requires
clarification. The utility of LAM in sputum samples has, hitherto, not been evaluated.
Methods: LAM was measured in sputum and urine samples obtained from 500 consecutively recruited ambulant patients,
with suspected TB, from 2 primary care clinics in South Africa. Culture positivity for M. tuberculosis was used as the reference
standard for TB diagnosis.
Results: Of 440 evaluable patients 120/387 (31%) were HIV-infected. Urine-LAM positivity was associated with HIV positivity
(p = 0.007) and test sensitivity, although low, was significantly higher in HIV-infected compared to uninfected patients (21%
versus 6%; p,0.001), and also in HIV-infected participants with a CD4 ,200 versus .200 cells/mm3 (37% versus 0%;
p = 0.003). Urine-LAM remained highly specific in all 3 subgroups (95%–100%). 25% of smear-negative but culture-positive
HIV-infected patients with a CD4 ,200 cells/mm3 were positive for urine-LAM. Sputum-LAM had good sensitivity (86%) but
poor specificity (15%) likely due to test cross-reactivity with several mouth-residing organisms including actinomycetes and
nocardia species.
Conclusions: These preliminary data indicate that in a high burden primary care setting the diagnostic usefulness of urine-
LAM is limited, as a rule-in test, to a specific patient subgroup i.e. smear-negative HIV-infected TB patients with a CD4 count
,200 cells/mm3, who would otherwise have required further investigation. However, even in this group sensitivity was
modest. Future and adequately powered studies in a primary care setting should now specifically target patients with
suspected TB who have advanced HIV infection.
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Introduction
Tuberculosis (TB) kills almost two million people annually [1]
and is out of control in Sub-Saharan Africa where up to 80% of
TB patients may be co-infected with HIV [2]. Current tools for the
diagnosis of TB are suboptimal and this contributes to poor
control [3]. Delayed diagnosis facilitates disease transmission,
increases healthcare costs, increases mortality, and causes greater
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lung damage resulting in chronic disability [4]. These drawbacks
are exacerbated in HIV-infected patients, where the diagnostic
‘gap’ is the widest - smear-positivity in this sub-group is as low as
20% [5], and the clinical and the radiological features are often
atypical [6]. Mycobacterial culture results are only available after
several weeks, if at all, in resource-poor settings [7]. Newer
technologies such as the T cell assays are not useful as rule-in tests
for the diagnosis of active TB in adults [8], and molecular assays
[7] are not widely available in high burden countries. The search
for a rapid point-of-care (POC) test continues [9].
More recently a standardised and commercially available
lipoarabinomannan (LAM) antigen-detection assay has been
developed (ClearviewH TB ELISA, Inverness Medical Innova-
tions, USA; see http://www.clearview.com/tb_elisa.aspx), which
now supersedes a pre-commercial prototype (MTB LAM ELISA
TestH, Chemogen, Portland, USA) first tested in 2005 in Tanzania
[10], and based on earlier developmental studies [11,12]. This test
option is attractive because urine is a sterile and easily obtainable
biological fluid that can be assayed even in sputum scarce patients.
Moreover, the assay has potential to be applied to other biological
fluids e.g. cerebro-spinal fluid [13] and pleural fluid [14], and a
user-friendly dipstick prototype of the test has been developed and
is currently being validated as a POC test.
Recent studies have shown that urine LAM may have
diagnostic value in HIV-infected [15,16,17,18] but not in HIV-
uninfected TB suspects [19]. However, studies that have stratified
LAM outcomes by CD4 count are limited [15,18] and there are
no published data on CD4-stratified LAM-related outcomes in
unselected TB suspects from a primary care setting. This
information is crucial as most TB cases present to, and are
diagnosed in primary care facilities in high burden settings. Thus,
although it is known that LAM may be useful in HIV-infected
patients [15,18] the precise subgroups that may benefit from this
test in a high burden primary care setting remain unknown.
Another unresolved question, because there are currently no data,
is whether the standardized urine ClearviewH LAM ELISA assay
has diagnostic utility when a sputum sample, in contrast to a urine
sample, is used. Thus, the aims of the study were to determine the
diagnostic accuracy of urine LAM in HIV-infected patients
belonging to different CD4 T cell categories and to compare
performance outcomes when using urine and sputum samples.
To address these questions, the ClearviewH LAM ELISA was
applied to concurrently collected urine and sputum samples. The
assay is indicated for use with urine samples from HIV-infected
subjects and thus the off-label evaluation of sputum specimens was
exploratory.
Methods
Ethics Statement
Written informed consent was obtained from all participants
and the study was approved by the University of Cape Town
Human Research Ethics Committee.
Study Sites and Population
500 consecutive ambulant self-reporting TB suspects ($18 years
of age) were recruited from 2 primary care clinics in Cape Town,
South Africa (Langa Clinic is a primary health care facility in a
disadvantaged Black African township with a high HIV preva-
lence, and Chapel Street is an inner-city clinic in a deprived area
with a lower prevalence of HIV and a higher proportion of
patients of mixed race).
All patients with symptoms suggestive of pulmonary TB were
invited to participate in the study (any one of persistent fever, night
sweats, cough of more than 2 weeks duration, hemoptysis, chest
pain, loss of weight and/or appetite, and generalized fatigue).
Detailed demographic information, clinical history and physical
characteristics were recorded by a trained researcher on a
standardized and validated case record form.
An HIV test was performed in all consenting study participants
after appropriate counseling. Where a test result was positive, a
CD4 count was also determined. Urine and a sputum samples
were collected from each participant for LAM detection. A further
2 sputum samples were collected for routine fluorescence smear
microscopy after centrifugation. These sputum samples were also
cultured for Mycobacterium tuberculosis (BACTEC MGIT 960, BD
Diagnostics, USA). Standard chest radiography, and a urine
dipstick test (UriCHECK 9, RapiMed Diagnostics, SA) to assess
for proteinuria and leukocytosis, was performed in all patients.
Treatment for TB was at the discretion of the attending physician.
Tuberculosis Case Definitions
Based on clinical, radiological and microbiological criteria and
the clinical impression of the attending physician, each patient was
allocated to one of 4 diagnostic categories by a study investigator
blinded to the LAM results. The reference standard was culture
positivity for M tuberculosis. To avoid incorporation bias, the LAM
ELISA results were not used to determine final TB status.
The categories were as follows:
1. Definite TB: A clinical presentation compatible with TB with
at least 1 positive culture (from any specimen) for M. tuberculosis
with response to anti-TB therapy [20].
2. Probable TB: A clinical-radiological picture highly suggestive
of TB and/or anti-TB treatment initiated by the attending
clinician based on clinical suspicion, but not meeting the above
criteria for definite TB.
3. Non-TB: no evidence of TB based on smear microscopy and
culture, and no radiological evidence to support the diagnosis
of active TB, with or without an alternative diagnosis being
established on patient follow-up.
4. Indeterminate TB: either the culture or CXR result (or
both) were unavailable, and the patient was lost to follow-up or
transferred to another centre, thus making it impossible to
confidently rule-out or rule-in TB. These patients were
excluded from the analysis.
Patients with TB and where relevant, non-TB cases, were
followed up for at least 2 months to determine clinical response to
therapy, and to confirm symptomatic recovery.
LAM determination in urine and sputum
Mid-stream urine samples and sputum samples, collected in
separate sterile containers from each patient at the clinic, were
transported to the laboratory within 3 hours. A technician blinded
to all clinical details and reference test results immediately
processed the urine samples according to the manufacturer’s
instructions (Clearview TBH ELISA, Inverness Medical Innova-
tions, U.S.A.). Briefly, an aliquot of each urine specimen was
heated, cooled and then centrifuged, and the supernatants frozen
at 280uC prior to batched ELISA testing. The sputum samples
underwent liquefaction (addition of twice the volume of 0.1%
DTT) prior to being processed and then frozen as for urine. Urine
and sputum supernatants were thawed usually within 2–3 weeks of
collection, and further processed according to the manufacturer’s
instructions. The plates were read immediately after processing at
450 nm on an ELISA plate reader (Anthos Labtec HT3).
Duplicate positive and negative controls were performed with
LAM in TB Suspects
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each run. Results were determined as the average of duplicate
optical density (OD) readings for each sample minus [the average
negative control OD reading plus 0.1], and using a cut-off of
‘‘zero’’ for positive and negative results.
Detection of LAM in bacteria, other than M. tuberculosis,
from sputum samples
Although not part of our original protocol, because early data
showed poor specificity of sputum LAM (i.e. high positivity in non
TB participants), we decided to investigate the likely cause by
testing cultures and culture supernatants of mouth flora and
specific organisms known to be mouth commensals e.g. aerobic
Actinomycetes, which also contain LAM-like glycolipids in their
cell walls. The organisms tested were isolated from the sputum
samples of ,15 non-TB patients. Multiple cultures were plated
from these samples obtained from patients were not in any way
matched to the study subjects. We therefore cultured a range of
different microbes, including Nocardia and Streptomyces species
(strain-typed where possible), C.albicans, T. paurometabolum, and C.
neoformans. These microbes were all originally isolated from oral
flora. Cultures were performed in both normal broth culture
(containing yeast extract) and Todd-Hewitt culture media (without
yeast extract). We also included normal oral flora from healthy
controls containing mixed bacterial growth, predominantly
viridans Streptococci. Microbial cultures were incubated at 37uC
for 3–5 days, culture supernatants removed and the pellets
resuspended in PBS. The LAM detection assay was performed as
described above.
Statistical Analysis
Sample size calculations were based on the assumption that
30% of 500 patients would have definite TB, and the resulting
numbers would be sufficient to estimate the test sensitivity and
specificity with a 64% precision. Test accuracy results were
computed as sensitivity, specificity and predictive values, along
with 95% confidence intervals (CI). Stata IC, version 10 (Stata
Corp, Texas, USA) was used for the logistic regression and Chi-
squared analyses. In addition, multivariable, logistic regression
analysis was conducted using culture-positive TB as the outcome
to determine the incremental value of urine LAM over sputum
smear alone and sputum LAM over both smear and urine LAM
[21]. Receiver Operating Characteristic (ROC) curves of the
logistic models were compared, where possible, to assess the
overall accuracy and added value of both urine and sputum LAM
[22,23].
Results
Demographic and clinical characteristics
Sixty patients were excluded from further analysis because their
TB status could not be reliably determined (see TB case definitions
above), leaving 440 evaluable patients. Figure 1 shows the study
recruitment flow chart including the patient numbers stratified by
patient subgroups, smear microscopy, HIV status and CD4 T cell
count. The demographic and clinical characteristics of the cohort,
stratified by HIV status, are shown in Table 1. The predominant
male and Black African population reflects the prevailing
demography of TB in South Africa. The prevalence of HIV in
the cohort was 31% and the median CD4 count in the HIV-
infected population was 177 cells/mm3.
Sensitivity of urine LAM versus smear microscopy in
different categories of TB suspects
The sensitivity of urine LAM alone, smear microscopy alone,
and urine LAM in combination with smear microscopy (using
culture-positivity as a reference standard) is shown in Figure 2.
Smear microscopy had a sensitivity of 65%, 49% and 37% in
unselected TB patients, in HIV co-infected patients, and in those
Figure 1. Flow chart of patients recruited to the study stratified by patient subgroup, smear microscopy, HIV status, and CD4 T cell
count.
doi:10.1371/journal.pone.0009848.g001
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with a CD4 count ,200 cells/mm3 respectively. By contrast,
urine LAM had comparative sensitivities in the same groups of
13%, 21% and 37%, respectively. Thus, whilst the sensitivity of
smear microscopy decreased significantly with increasing immune
paresis (HIV-infected vs uninfected and CD4,200 vs .200) that
of urine LAM increased significantly (Figure 2; p#0.003). Smear
microscopy was significantly more sensitive than urine LAM in all
groups except TB patients with a CD4 count ,200 cells/mm3,
where sensitivities were equivalent. However, in this group with
advanced HIV, the urine LAM assay and smear microscopy had
non-redundant overlap i.e. the 2 tests tended to identify different
patients. Thus, in TB patients with a CD4 count ,200 cells/mm3
a combination of urine LAM and smear microscopy showed a
sensitivity of 53% versus 37% for smear-microscopy alone;
however, this additive value of urine LAM did not reach statistical
significance (p= 0.07). Because of the smaller number of HIV-
infected patients, comparative incremental multivariable ROC
analyses could not be performed in this subgroup.
Collectively, these data indicate that 25% of HIV-infected
smear-negative TB patients with a CD4 count ,200 cells/mm3
had a positive urine LAM test (Figure 2). Moreover, in the smear
negative/culture positive group, a significantly greater percentage
of patients with CD4 count ,200 cells/mm3 were urine LAM
positive compared to those with CD4 count .200 cells/mm3
(p = 0.003; Figure 2). The same pattern was seen when the definite
TB plus probable TB groups were combined for analysis (data not
shown).
Specificity of the urine LAM assay
The specificity of urine LAM and smear microscopy, using the
non-TB group as a reference, in the different patient subgroups is
shown in Figure 2. In summary, LAM was highly specific (95 to
100%) in all subgroups but specificity was comparatively lowest in
the CD4,200 cells/mm3 subgroup (but not statistically different
from other subgroups). Thus urine LAM is a reasonable rule-in
test for active TB in those with a CD4 count ,200 cells/mm3
(sensitivity = 37% and specificity = 95%).
Association of urine LAM with HIV status and urine
protein
Urine LAM positivity was significantly higher in HIV-infected
vs uninfected subjects (21% vs 6%; p,0.001; Figure 2) and those
with a CD4 count ,200 cells/mm3 vs .200 cells/mm3 (37% vs
0%; p= 0.003; Figure 2). In the univariate analysis a positive urine
LAM result was associated with HIV positivity (OR=4.75;
p = 0.002), but inversely associated with low weight (OR=0.94;
P= 0.01), and previous TB (OR=0.09; p = 0.02). However, in the
multivariable analysis LAM positivity was independently associat-
ed only with HIV positive status (OR=3.2; P = 0.04) and lack of
previous TB (OR=0.09; P= 0.02).
In HIV-infected culture positive TB patients (n = 36) there was
no association between urine LAM and proteinuria measured
through urine dipstix readings i.e there was no significant
difference between the proportion of patients who were urine
LAM positive in those who did and did not have proteinuria on
dipstick examination [6/24 (25%) vs 2/12 (17%)].
Sputum LAM performance outcomes
Of the 440 evaluable patients sputum samples were available for
LAM analysis in 377 patients. Compared to urine LAM, sputum
LAM had a higher sensitivity (86%; 95%CI 81, 90%) but poorer
specificity (15%; 95% CI 10, 21%; Table 2). Cultures of oral flora
from non-TB patients and of specific microbes known to reside in
the oral cavity tested positive for LAM using the ELISA kit
(Figure 3). In the multivariable analysis, sputum LAM did not add
significantly to the overall accuracy beyond urine LAM and smear
microscopy (area under the ROC of 85.15% vs 83.96%, p= 0.14)
[ROC curves not shown].
Discussion
In this study we show that in unselected HIV-infected or
uninfected ambulant TB suspects LAM has little clinical utility in a
high burden primary care setting (poor sensitivity of only 13% and
21%, respectively in these subgroups). However, in the diagnos-
tically challenging smear negative/culture positive HIV-infected
subgroup with a CD4 count ,200 cells/mm3, 25% of patients
(n = 19) had a positive urine LAM. The high specificty of the assay
thus makes urine LAM a potential rule-in test for active TB within
this sub-group. At first glance the sensitivity of 25% in this
subgroup appears low, but given the high specificity of the assay,
its modest cost, generation of results within 24 hours (potentially
even faster, if a LAM strip test can be commercialized), the lack
of other alternative rapid diagnostic options, the diagnostic
Table 1. Clinical and demographic characteristics of 440
evaluable TB suspects, stratified by HIV status.
N (%)
HIV
positive**
(%)
HIV
negative**
(%)
P
value
Total TB suspects
included
440 (100) 120 (27.3) 267 (60.7)
Age, mean (SD) 41 (12) 38 (10) 42 (13) 0.0006
Sex
Male 291 (66.1) 61 (21) 195 (67)
Female 149 (33.9) 59 (39.6) 72 (48.3) ,0.001
Race
Black 314 (71.4) 97 (30.9) 178 (56.7)
Mixed ancestry
(coloured)
118 (26.8) 22 (18.6) 82 (69.5)
White 8 (1.8) 1 (12.5) 7 (87.5) 0.015
Weight in Kg,
mean (SD) (n=410)*
61.2 (11.9) 58.3 (10.1) 62.0 (12.2) 0.0052
Previous TB
Yes 161 (36.6) 46 (28.6) 101 (62.7)
No 279 (63.4) 74 (26.5) 166 (59.5) 0.924
Current Smoker
(n=437)*
Yes 252 (57.3) 55 (21.8) 170 (67.5)
No 185 (42.0) 65 (35.1) 95 (51.4) 0.001
Urine protein
(n=384)*
+ 32 (7.3) 13 (40.6) 18 (56.3)
++ 15 (3.4) 4 (26.7) 10 (66.7)
+++ 3 (0.7) 0 (0) 3 (100)
Negative 334 (75.9) 91 (27.2) 210 (62.9) 0.3624
CD4 count, median
(cells/mm3)(n=111)*
– 177 – –
*Irreconcilable ambiguity on the request form precluding processing of sample,
or patient consented but did not turn up for the test.
**Excludes 42 (9.5%) patients who refused HIV testing and 11 (2.5%) patients
who had no data.
doi:10.1371/journal.pone.0009848.t001
LAM in TB Suspects
PLoS ONE | www.plosone.org 4 March 2010 | Volume 5 | Issue 3 | e9848
conundrum presented by these cases [5], and that a point-of-care
(POC) test format is currently being validated, makes urine LAM a
potentially useful assay. Moreover, other established TB tests such
as nucleic acid amplification tests have a sensitivity (,30%) within
a similar range, and a high accompanying specificty when used
clinically as rule-in tests for extra-pulmonary TB [24].
In this study, we have attempted to define the specific utility of
urine LAM within a primary care population with a high
prevalence of HIV. Other investigators have found that urine
LAM sensitivity in smear-negative TB, using the pre-commercial
version, varied between 28% to 56% [15,17,18]. However, urine
LAM outcomes stratified by CD4 count were not available in two
of the studies [16,17], and specificity was suboptimal in both of
them (discussed later). Thus, there are no existing data about urine
LAM outcomes in specific CD4 categories in patients who present
to primary care clinics with suspected TB. This information is
crucial because the vast majority of TB suspects from resource-
poor settings present to primary care facilities. If additional studies
confirm our findings, there is potential to develop an algorithm
where patients who are smear negative, HIV positive and have a
CD4 count ,200 cells per mm3 may be ideal candidates for the
urine LAM assay (especially the POC version). It is this very
population that poses a diagnostic conundrum for clinicians
because of the atypical radiological picture and the high
proportion of smear negativity. Given the wide-spread availability
of rapid HIV testing, and in the near future, POC CD4 tests, we
believe that urine LAM could easily be incorporated into a
diagnostic algorithm for TB. Thus, our work has identified a
specific subgroup that should now be targeted in future studies so
that the utility of the urine LAM assay in HIV-infected subjects
can be further clarified. Future studies should also evaluate the
efficiacy and cost-effectiveness of an primary care algorithm-based
approach using urine LAM.
The specificity of the urine LAM assay was high, although it was
lower in those with a CD4 count, 200 cells/ml, and similar to
studies done in hospitalised patients with suspected TB [18] and in
individuals being screened for TB prior to antiretroviral therapy
[15]. This contrasts with the poorer specificity of approximately
88% in three other studies [16,17,19]. This may possibly be
explained by undiagnosed occult TB disease and may also explain
the lower specificty in our study in the most immunocomprimised
patients. Other reasons may include possible detection of antigen
Figure 2. The sensitivity and specificity (and 95% confidence intervals (%); top panel of table) and positive and negative predictive
value (middle panel of table) of smear-microscopy alone, urine LAM alone, and a combination of urine LAM and smear-microscopy.
The bottom panel of the table shows the test sensitivity in smear negative culture positive TB patients. For sensitivity calculations the definite TB
group (n = 141) was used whilst specificity calculations were performed using the non-TB group (n = 172) as a reference.
doi:10.1371/journal.pone.0009848.g002
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from latently-infected subjects, contamination of the sample by
environmental pathogens or rapidly dividing bacteria (particularly
if the sample was collected at home and brought to the clinic), or
contamination by non-bacterial species e.g. Candida, which is
prevalent in HIV-infected populations. These possibilities are
tenable given our findings that several organisms, including
Candida species, cross-react with the polyclonal LAM antibodies
within the assay. In our study urine was collected at the clinic in
sterile containers; however, the collection methods used in the
other studies were not described.
Figure 3. LAM positivity (. zero OD units = positive for LAM after subtraction of the negative control i.e. cutpoint is zero) in
cultures of oral mouth flora (oral flora) and in organism-specific cultures (various Actinobacteria, including different strains of
Nocardia and Streptomyces, and C. albicans, T. paurometabolum, and C. neoformans inoculated into normal broth culture [containing
yeast extract] and Todd-Hewitt culture media [without yeast extract]. Normal oral flora from six different healthy control subjects was also
cultured).
doi:10.1371/journal.pone.0009848.g003
Table 2. Measures of accuracy for sputum LAM in definite TB patients, and in definite plus probable TB patients, stratified by HIV
status and CD4 count.
Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI)
Definite TB
(culture pos)
(Non-TB group used for specificity calculations)
All patients 86 (81, 90) 15 (10, 21) 60 (54, 65) 42 (30, 56)
HIV neg patients 84* (74, 91) 16 (10, 24) 40 (32, 48) 60 (41, 77)
HIV pos patients 100* (90, 100) 7 (2, 19) 46 (35, 57) 100 (44, 100)
CD4 ,200 94# (72, 99) 50 (33, 67) 50 (33, 67) 94 (72, 99)
CD4 $200 100# (82, 100) 17 (6, 39) 53 (36, 69) 100 (44, 100)
Definite TB and Probable TB
(Non-TB group used for specificity calculations)
All patients 86 (81, 90) 15 (10, 21) 60 (54, 65) 42 (30, 56)
HIV neg patients 82** (75, 88) 16 (10, 24) 57 (50, 64) 39 (26, 55)
HIV pos patients 92** (82, 96) 7 (2, 19) 59 (48, 68) 38 (14, 69)
*p,0.0001 (comparison of sputum LAM sensitivity in HIV positive vs HIV negative definite TB cases).
#p=0.0131 (comparison of sputum LAM sensitivity in HIV positive subjects with a CD4 count $200 vs CD4 count ,200 cells/mm3).
**p = 0.04 (comparison of sputum LAM sensitivity in HIV positive vs HIV negative definite plus probable TB cases).
doi:10.1371/journal.pone.0009848.t002
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The urine ClearviewH LAM ELISA used in this study is the
current commercially-available version, and supersedes the prior pre-
commercial prototype (MTB LAM ELISA; Chemogen, Portland,
USA). Although the polyclonal antibody used in the ClearviewH
LAM ELISA is the same as in the pre-commercial version, there are
differences in the manufacturing technology and protocols used (e.g.
antibody coating technologies used etc).Whether this may impact test
performance, and make the different versions incomparable, seems
unlikely but remains a possibility given that several technical factors
may impact on ELISA test performance [25].
Our test sensitivity of 21% is much lower than the sensitivity of
61% found by Reither et al in ambulant HIV-infected Tanzanian
TB suspects using the Chemogen MTB ELISA [17], 52% by
Mutetwa et al in HIV-infected ambulant Zimbabwean TB suspects
using the same prototype [16], and 38% found by Lawn et al in
ambulant South African HIV-infected patients being screened
prior to the initiation of HAART also using the pre-commercial
prototype [15]. How do we explain these inconsistent findings?
Our patients were less immuno-suppressed (median CD 4 count
of = 177) than other cohorts [15,17,18]; there appears to be a
crude inverse relationship between CD4 T cells count and urine
LAM sensitivity [15,17,18]. Furthermore, ambulant patients in
our study may have presented earlier with less advanced disease
given the better health care infrastructure in South Africa
compared with Tanzania. Other factors such as strain type,
population genetics and malnutrition, though unproven, may also
have played a role. Another possibility is population-specific
heterogeneity [26] and differential HIV-related glomerular
podocyte dysfunction, which determines the ‘leakiness’ of the
renal glomerulus for proteins [27]. However, the lack of
association between urine LAM and proteinuria in our study, in
contrast to that of Reither et al [17], argues against this hypothesis.
The standardized ClearviewH LAM ELISA has not previously
been evaluated using sputum samples. We hypothesised, based on
a prior study of LAM antigen in sputum [28], that detection of
LAM antigen in smear negative patients would be diagnostically
useful. However, although the ClearviewH TB ELISA had a high
sensitivity in sputum samples, the specificity was dismally poor. We
determined that this was probably due to cross-reactivity with
LAM-like microbial carbohydrate surface molecules in the cell
walls of several mouth-residing organisms such as Candida, and
many species of Actinobacteria. Colonisation by Candida, or else
mucosal or systemic candidiasis (e.g. mouth and genitals), may also
possibly explain the lower specificity of the LAM assay seen in high
HIV prevalence populations in other settings [16,17,19]. Certainly
the polyclonal antibodies contained within the test, despite not
cross-reacting with common pathogens like E. coli, S. pneumoniae etc
[10], are not specific for mycobacterial species.
A limitation of our study is the low number of HIV-infected
definite TB cases who were smear negative and had a CD4 count
less than 200 cells/mm3 (n= 19), and the resulting wide confidence
intervals in this subgroup. Given that our study was not adequately
powered to evaluate outcomes in HIV-infected individuals with
advanced immunosuppression our findings can only be regarded as
preliminary. Thus, even in a high HIV prevalence setting, large and
adequately powered studies will be required to recruit sufficient
patients with smear negative definite TB in the low CD4 count
subgroup to achieve reliable estimates of performance outcomes.
Although we found that urine LAM plus smear microscopy may be
more sensitive than smear microscopy alone in those with low CD4
counts, this was not statistically significant (p= 0.07). This is likely
due to type II error and the low sample numbers in the low CD4
subgroup. Larger and adequately powered studies targeting this
particular subgroup are now required to clarify utility.
In conclusion, LAM is not a useful assay in unselected TB
suspects in a primary care setting. However, a targeted approach
to using LAM may be useful in those who have advanced HIV
infection, though, even in this group sensitivity is modest. We have
interpreted this positively given the prevailing diagnostic challeng-
es and lack of other diagnostic options within this subgroup. Our
findings, despite the limited assay sensitivity, may lend themselves
to useful application in diagnostic algorithms, incorporating CD4
count and smear status, within high burden countries. Larger
targeted studies, in the low CD4 count subgroup, in ambulant and
hospitalised TB populations from different geographical settings
are now required to validate this approach and clarify our findings.
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